Assoc. Prof. Ozan Balakan, M.D.

About Assoc. Dr. Ozan BALAKAN

Department: Medical Oncology
 
E-Mail Address: [email protected]

Foreign Language: English

Date of Birth: 1975

Education:

1981-1986; Kahramanmaraş Sakarya Primary School

1986-1989; Kahramanmaraş Cumhuriyet Secondary School

1989-1992; Kahramanmaraş İbrahim Çalık High School

2000; Istanbul University Faculty of Medicine, Bachelor's degree, and master's degree

2005; Dicle University Internal Medicine, Ph.D. / S. Proficiency / Specialization in Medicine 1

2012 Gaziantep University Medical Oncology, Ph.D. / S. Proficiency / Specialization in Medicine 2

Post Graduation Jobs:

2001-2005 Dicle University Faculty of Medicine. Internal Diseases AD Research Assistant

2005-2006 Osmaniye Private İbni Sina Hospital

2006-2007 Kahramanmaraş Private Vatan Medical Center

2007-2008 K.S.Ü Medical Faculty Internal Diseases Department

2008-2009 GATA Endocrinology BD, Ankara Medical Lieutenant

2009-2012 Gaziantep Univ. Faculty of Medicine. Medical Oncology

2012-2016 K.S.Ü Faculty of Medicine Medical Oncology

2016- K.S.Ü Faculty of Medicine Medical Oncology

MASTER’S THESIS TITLE AND THESIS ADVISORS

Thesis Title: –

Thesis advisor: –

Title of Doctorate Thesis / Proficiency Study / Medical Specialty Thesis (summary attached) and Advisor (s):

Thesis Title: Comparison of Plasma Cytokine and CD Levels in Patients with Chronic Delta Hepatitis, Chronic Hepatitis B and Healed Hepatitis B

Thesis Advisor: Assoc. Dr. Kendal Yalcin

Title of Doctorate Thesis / Proficiency Study / Medical Specialty Thesis (summary attached) and Supervisor (s):

Thesis Title: Investigation of the Relationship between Urotensin 2 and Clinical and Pathological Parameters in Breast Cancer

Thesis Advisor: Prof. Dr. Celaletdin Camci

Supervised Master Theses:

Supervised Doctoral Theses / Proficiency Studies in Art:

Prognostic Factors Affecting Survival in Patients with Stage 3 Non-Small Cell Lung Cancer

(Thesis Prepared by Dr. Ali Tur, 2014) (15 points)

DUTIES PERFORMED IN PROJECTS:

2002-2004 A 12-week open uncontrolled multicenter study evaluating the efficacy and safety of quinapril or quinapril plus hydrochlorothiazide in patients with mild to moderate hypertension code 9061007

2009-2012 Lume Lung 2: BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

2009-2012 AGENNIX FORTIS-M. A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens

2010-2012 Celltrion CTP-6 Breast ca da CTP-6 & Trastuzumab comparative efficacy study

2010-2012 CURRENT S A Study of Tarceva (Erlotinib) to Compare Two Different Doses in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)

2010-2012 BMS CA184-095 CA184-095: A randomized, double-blind, phase III trial to compare the efficacy of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC).

2010-2012 LOGİC EGF 110656 A phase III study of ERB2 positive advanced or metastatic gastric, esophageal or gastroesophageal junction adenocarcinoma treated with capecitabine plus oxaliplatin with or without lapatinib

2011-2012 Imclone CP12-0715 A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy

2011-2012 RO5185426 vemurafenib in metastatic malignant melanoma Humanitarian early access program

2012-2012 LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum-Based Chemotherapy

2009-2011 ML21440 A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer

Administrative Duties:

-Medical Oncology Department

Awards:

– Anatolian Medical Oncology Association Minor Research Assistant of the Year Award

-7. National Medical Oncology Congress best paper award 2010

Courses He Attended:

Training Received Under Good Clinical Practices:

2010 Sharing Program for Good Practice Principles in Clinical Research (Akademika 21-22 May 2010)

Publications:

Compositions

Articles published in international refereed journals:

  1. Articles Published in International Refereed Journals in SCCI, AHC1
  2. Sayarlıoğlu M, Sayarlıoğlu H, Özkaya M, Balakan O, Uçar MA. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome and adult-onset Still’s disease: case report and review of the literature. Mod Rheumatol. 2008;18(4):403-6.
  3. Pehlivan Y, Turkbeyler IH, Balakan O, Sevinc A, Yilmaz M, Bakir K, Onat AM. Possible anti-metastatic effect of Iloprost in a patient with systemic sclerosis with lung cancer: a case study. Rheumatol Int. 2011 Mar 30.
  4. Inal A, Kos FT, Algin E, Yildiz R, Dikiltas M, Unek IT, Colak D, Elkiran ET, Helvaci K, Geredeli C, Dane F, Balakan O, Kaplan MA, Durnali AG, Harputoglu H, Goksel G, Ozdemir N, Buyukberber S, Gumus M, Kucukoner M, Ozkan M, Uncu D, Benekli M, Isikdogan A. Gemcitabine Alone versus a combination of Gemcitabine and Cisplatin for the Treatment of Patients with Locally Advanced and/or Metastatic Pancreatic Carcinoma: A Retrospective Analysis of multicenter study (Anatolian Society of Medical Oncology). Neoplasma. 2012;59(3):297-301.
  5. Inal A, Kos FT, Algin E, Yildiz R, Berk V, Tugba Unek I, Colak D, Colak D, Kucukoner M, Tamer Elkiran E, Helvaci K, Geredeli C, Dane F, Balakan O, Ali Kaplan M, Gok Durnali A, Harputoglu H, Goksel G, Ozdemir N, Buyukberber S, Gumus M, Ozkan M, Benekli M, Isikdogan A, Anatolian Society Of Medical Oncology. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: a retrospective analysis of a multicenter study. J BUON. 2012 Jan-Mar;17(1):102-5.
  6. Babacan T, Sevinc A, Akarsu E, Balakan O. Sunitinib-Induced Autoimmune Thyroiditis in a Patient with Metastatic Renal Cell Carcinoma: A Case Report. Chemotherapy. 2012 May 12;58(2):142-145.
  7. Berk V, Ozdemir N, Ozkan M, Aksoy S, Turan N, Inal A, Balakan O, Yasar N, Unal OU, Benekli M, Durnali A, Colak D, Sonmez OU. XELOX versus FOLFOX4 as Second-Line Chemotherapy in Advanced Pancreatic Cancer. Hepatogastroenterology. 2012 Apr 25;59(120)
  8. Balakan O, Süner A, Yiğiter R, Balakan T, Sirikçi A, Sevinç A. Long-term survival in metastatic malignant melanoma: ipilimumab followed by vemurafenib in a patient with brain metastasis. Intern Med. 2012;51(19):2819-23. Epub 2012 Oct 1.
  9. Turan N, Benekli M, Koca D, Ustaalioglu BO, Dane F, Ozdemir N, Ulas A, Oztop I, Gumus M, Ozturk MA, Berk V, Kucukoner M, Uner A, Balakan O, Helvaci K, Ozkan S, Yilmaz U, Buyukberber S; Anatolian Society of Medical Oncology. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer. Oncology. 2013;84(1):14-21 (0.14×30=4.2 points)
  10. Demirci U, Tufan G, Aktas B, Balakan O, Alacacioglu A, Dane F, Engin H, Kaplan MA, Gunaydin Y, Ozdemir NY, Tugba Unek I, Karaca H, Akman T, Sonmez OU, Coskun U, Harputluoglu H, Sevinc A, Tonyali O, Buyukberber S, Benekli M. Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). J Cancer Res Clin Oncol. 2013 Feb 12. (0.14×30=4.2 points)
  11. Inal A, Akman T, Yaman S, Demir Ozturk S, Geredeli C, Bilici M, Inanc M, Harputoglu H, Demirci U, Balakan O, Yesil Cinkir H, Alici S, Uysal Sonmez O, Goksel G, Gokoz Dogu G, Umit Unal O, Tamozlu T, Buyukberber S, Melih Boruban C, Isikdogan A. Endocrine therapy alone vs. chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node-positive breast cancer: a retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology). J BUON. 2013 Jan-Mar;18(1):64-9. (0.14×30=4.2 points)
  12. Balakan O, Babacan T, Altundag K. Vemurafenib-induced hypertension: is it real? J BUON. J BUON. 2013 Apr-Jun;18(2):545. (0.72×30=21.6 points)
  13. Babacan T, Sarici F, Gokhan A, Balakan O, Keskin O, Altundag K. Granulocyte colony-stimulating factor-induced tumor lysis-like syndrome: leucosis. J BUON.2013 Apr-Jun; 18(2):549-50 (0.23×30=6.9 points)
  14. Sarici F, Babacan T, Altundag K, Balakan O, Gullu I. Successful treatment of benign metastasizing leiomyoma with oral alternated chemotherapeutic agents. J BUON. 2013 Jul-Sep;18(3):799. (0.28×30=8.4 points)
  15. Kefeli U, Benekli M, Sevinc A, Yildiz R, Kaplan MA, Ciltas A, Balakan O, Isikdogan A, Coskun U, Dane F, Harputluoglu H, Karaca H, Yazilitas D, Durnali A, Kaya AO, Demirci U, Gumus M, Buyukberber S. Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience. Oncol Lett. 2013 Aug;6(2):605-611. Epub 2013 Jun 17. (0.14×30=4.2 points)
  16. Inal A, Akman T, Yaman S, Ozturk SC, Geredeli C, Bilici M, Inanc M, Harputoglu H, Demirci U, Balakan O, Cınkır HY, Alıcı S, Colak D, Sonmez OU, Goksel G, Dogu GG, Engin H, Unal OU, Tamozlu T, Buyukberber S, Boruban CM, Isıkdogan A. Pathologic and clinical characteristics of elderly patients with breast cancer: a retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology). Int Surg. 2014 Jan-Feb;99(1):2-7. (0.14×30=4.2 points)
  17. Berk V, Kaplan MA, Tonyali O, Buyukberber S, Balakan O, Ozkan M, Demirci U, Ozturk T, Bilici A, Tastekin D, Ozdemir N, Unal OU, Oflazoglu U, Turkmen E, Erdogan B, Uyeturk U, Oksuzoglu B, Cinkir HY, Yasar N, Gumus M. Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the Anatolian society of medical oncology. Asian Pac J Cancer Prev. 2013;14(12):7367-9. (0.14×30=4.2 points)
  18. Babacan T, Turkbeyler IH, Dag MS, Dilli I, Balakan O, Altundag K. Cetuximab-induced esophageal ulcer: the first report in the literature. Libyan J Med. 2014 Feb 24;9:23723. (0.23×30=6.9 points)
  19. Babacan T, Türkbeyler IH, Balakan O, Pehlivan Y, Suner A, Kısacık B. A case of vemurafenib-induced polyarthritis in a patient with melanoma: how to manage it? Int J Rheum Dis. 2014 May 12. (0.23×30=6.9 points)
  20. Gogebakan B, Bayraktar R, Suner A, Balakan O, Ulasli M, Izmirli M, Oztuzcu S, Camci C. Do fasudil and Y-27632 affect the level of transient receptor potential (TRP) gene expressions in breast cancer cell lines? Tumour Biol. 2014 Aug;35(8):8033-41. (0.18×30=5.4 points)
  21. Balakan O, Kalender ME, Suner A, Cengiz B, Oztuzcu S, Bayraktar R, Borazan E, Babacan T, Camci C. The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer. Med Sci Monit. 2014 Aug 12;20:1419-25. (0.41×30=12.3 points)
  22. Alıcı H, Balakan O, Ercan S, Çakıcı M, Yavuz F, Davutoğlu V. Evaluation of early subclinical cardiotoxicity of chemotherapy in breast cancer. Anadolu Kardiyol Derg. 2015 Jan;15(1):56-60. (0.23×30=6.9 points)
  23. Unal OU, Oztop I, Kos T, Assoc, Turan N, Kucukoner M, Helvaci K, Berk V, Sevinc A, Yildiz R, Cinkir Hy, Tonyali O, Demirci U, Aktas B, Balakan O, Yilmaz AU. Prognostic factors and adjuvant treatments for surgically treated cancers of the biliary tract: a multicentre study of the Anatolian Society of Medical Oncology (ASMO). Asian Pac J Cancer Prev. 2014;15(22):9687-92. (0.14×30=4.2 points)
  24. Kalender ME, Buyukhatipoglu H, Balakan O, Suner A, Dirier A, Sevinc A, Bulbul F, Tatli AM, Ulas T, Camci C. Depression, anxiety and quality of life through the use of complementary and alternative medicine among breast cancer patients in Turkey. J Cancer Res Ther. 2014 Oct-Dec;10(4):962-6. (0.14×30=4.2 points)
  25. Buyukhatipoglu H, Babacan T, Kertmen N, Balakan O, Suner A, Ates O, Sarici F, Aslan A, Diker O, Tasdemir V, Ozisik Y, Altundag K. A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple-negative early-stage breast cancer. J BUON. 2015 Jan-Feb;20(1):22-7. (0.14×30=4.2 points)
  26. Babacan T, Balakan O, Kuzan TY, Sarici F, Koca E, Kertmen N, Petekkaya I, Altundag K. The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+ breast cancer patients. J BUON. 2015 Jan-Feb;20(1):50-6. (0.28×30=5.4 points)
  27. 26. Babacan T, Efe O, Hasirci AS, Demirci F, Buyukhatipoglu H, Balakan O, Sarici F, Kertmen N, Esin E, Akin S, Ates O, Aksoy S, Sever AR, Altundag K. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Tumori. 2015 Apr 27;101(4):418-423. (0.14×30=4.2 points)
  28. Babacan T, Buyukhatipoglu H, Balakan O, Kertmen N, Suner A, Sarici F, Akin S, Ates O, Karakas Y, Aslan A, Diker O, Altundag K. Chemotherapy might not be beneficial in lymph node-negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis. J BUON. 2015 Mar-Apr;20(2):479-86.(0.14×30=4.2 points)
  29. Baykara M, Benekli M, Ekinci O, Irkkan SC, Karaca H, Demirci U, Akinci MB, Unal OU, Dane F, Turkoz FP, Balakan O, Eser EP, Ozturk SC, Ozkan M, Oksuzoglu B, Sevinc A, Demir N, Harputluoglu H, Yalcin B, Coskun U, Uner A, Ozet A, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers. J Gastrointest Surg. 2015 Sep;19(9):1565-71.(0.14×30=4.2 points)

Ab. Articles Published in Other International Journals

  1. Akkoyun M, Ardıç I, Balakan O, Deniz MS, Acar G. Case images: Isolated thrombus-like mass in a patient with multiple myeloma. Turk Kardiyol Dern Ars. 2014 Jun;42(4):413 (0.28×20=5.6 points)
  2. Mehmet K, Sener C, Uyeturk U, Seker M, Tastekin D, Tonyali O, Balakan O, Yazici OK, Urakci Z, Isikdogan A, Ozdemir N, Inal A, Kaplan MA, Suner A, Dal S, Uncu D, Gumus M, Boruban MC, Oksuzoglu B, Ayyildiz O, Benekli M. Treatment modalities in primary gastric lymphoma: the effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical Oncology. Contemp Oncol (Pozn). 2014;18(4):273-8. (0.14×25=3.5 points)
  3. Suner A, Buyukhatipoglu H, Balakan O, Kalender ME, Ulas T, Sevinc A, Camci C. Importance of HER2 Work-Up and Treatment Even in Patients with Poor Performance Status: A Case Report. Case Rep Oncol Med. 2014;2014:731581. (0.20×20=4 points)
  4. Ulasli M, Gurses S, Cengiz B, Oztuzcu S, Balakan O, Suner A, Gogebakan G, İgci M, Balik A, Arslan A, Camci C. Expression of PARP1 Gene in Breast Cancer Patients. UHOD , 2013 , 23 , 213-218. (0.14×25=3.5 points)
  5. Karaca H, Geredeli C, Kaplan MA, Demirci U, Alici S, Artac M, Isikdogan A, Benekli M, Balakan O, Arpaci E, Budakoglu B, Uncu D, Guler T, Berk V, Özkan M, “Efficacy And Safety Of Erlotinib In Previously Treated Advanced Non-Small Cell Lung Cancer”, UHOD, vol.23, pp.1-6, 2013. (0.14×25=3.5 points)
  6. Kucukoner M, Balakan O, Kaplan MA, Inal A, Alabalik U, Urakci Z, Dal MS, Yildiz Y, Isikdogan A. Helicobacter pylori in primary gastric lymphoma and gastric cancer: A clinicopathologic and prognostic assessment, Journal of Microbiology & Infectious Diseases; Jun2013, Vol. 3 Issue 2, p61-66, 6p. (0.14×20=2.8 points)
  7. Papers presented in international scientific meetings and published in the proceedings book:
  8. Acar G, Kaya H, Akcay A, Sökmen A, Balakan O, Köroglu S, Nacar AB, Suner A, Şahin M, Sökmen G, Sayarlioglu M, Tuncer C. Dıastolıc functıon abnormalıtıes ın patıents wıth Behcet’s dısease: a tıssue doppler study. 6th Congress of Update in Cardiology and Cardiovascular Surgery in conjunction with 59th International Congress of the European Society for Cardiovascular Surgery İzmir, Turkey 15–18 April 2010 İnternational journal of cardiology 140, supplement 1 (2010) s1–s93.
  9. A. Inal, A. Isikdogan, T. Kos, E. Algin, M. Gumus, M. Dikilitas, E. T. Elkiran, K. Helvaci, C. Geredeli, F. Dane, O. Balakan, A. Gok Durnali, H. Harputluoglu, G. Goksel, N. Ozdemir, S. Buyukberber, R. Yildiz, M. A. Kaplan, M. Ozkan, D. Uncu Gemcitabine alone versus gemcitabine plus cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic adenocarcinoma: A retrospective analysis of the multicenter study. ASCO 2011.Chicago.
  10. N. Turan, D. Koca, F. Dane, N. Özdemir, B. B. Oven Ustaalioglu, I. Oztop, A. Ulas, V. Berk, M. Kucukoner, O. Balakan, M. A. Ozturk, M. Benekli, M. Gumus, U. Yilmaz, S. Ozkan, S. Buyukberber. The impact of bevacizumab usage on patients who were curative resected for liver-confined metastases from colorectal cancer. ASCO 2011.Chicago.
  11. Balakan O, Süner A, Öztuzcu S, Cengiz B, Kalender ME, Özkara E, Camcı C. An analysis of the Relationship Between Urotensin 2 and Clinicopathological Parameters of Breast Cancer. Gaziantep University, School of Medicine. 1st NEMA Congress – 29 November- 02 December 2012 / Istanbul – Turkey.
  12. Çiltaş A, Büyükberber S, Yıldız R, Arpacı E, Budakoğlu B, Küçüköner M, Şendur MA, Balakan O, Kefeli U, Berk V, Harputluoğlu H, Öksüzoğlu B, Uncu D, Kaya AO, Alkış N, Gümüş M, Benekli M, Coşkun U. Effıcacy and toxıcıty evaluatıon of cısplatın + capecitabine chemotherapy ın locally advanced and metastatic gastrıc cancer patıents (Multicentric Study of the Anatolian Society of Medical Oncology). 1st NEMA Congress – 29 November- 02 December 2012 / Istanbul – Turkey. (0.14×7=0.98 points)
  13. Çiltaş A, Koca D, Yılmaz U, Büyükberber S, Eşbah O, İnal A, Öztop İ, Binicier Ö, Köş T, İnanç M, Öksüzoğlu B, Işıkdoğan A, Uncu D, Özkan M, Yazıcı ÖK, Balakan O, Sevinç A, Coşkun U, Benekli M. Retrospective evaluation of tolerability and efficacy of neo-adjuvant chemoradiotherapy in locally advanced rectal cancer patients. 1st NEMA Congress – 29 November- 02 December 2012 / Istanbul – Turkey. (0.14×7=0.98 points)
  14. İnal A, Akman T, Yaman S, Ozturk SD, Geredeli Ç, Bilici M, İnanc M, Harputoğlu H, Demirci U, Balakan O, Yesil Cınkır H, Alıcı S, Uysal Sonmez Ö, Göksel G, Gokoz Dogu G, Unal OU, Tamozlu T, Buyukberber S, Boruban CM , Isıkdogan A. Endocrine therapy alone versus chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node positive breast cancer: a retrospective analysis of multicenter study (Anatolian society of medical oncology). 1st NEMA Congress – 29 November- 02 December 2012 / Istanbul – Turkey.(0.14×7=0.98 points)
  15. İnal A, Akman T, Yaman S, Ozturk SC, Geredeli Ç, Bilici M, İnanc M, Harputoglu H, Demirci U, Balakan O, Yesil Cınkır H, Alıcı S, Colak D , Uysal Sonmez Ö, Goksel G, Gokoz Dogu G, Engin H, Unal OÜ, Tamozlu T, Buyukberber S, Boruban CM, Isıkdogan A. Pathological and clinical characteristics of elderly patients with breast cancer: multicenter study (Anatolian society of medical oncology). 1st NEMA Congress – 29 November- 02 December 2012 / Istanbul – Turkey. (0.14×7=0.98 points)
  16. İnal A, Akman T, Yaman S, Ozturk SC, Geredeli Ç, Bilici M, İnanc M, Harputoglu H, Demirci U, Balakan O, Yesil Cınkır H, Alıcı S, Uysal Sonmez Ö, Engin H, Unal OÜ, Tamozlu T, Isıkdogan A. Endocrine therapy alone versus chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node negative breast cancer: a retrospective analysis of multicenter study (Anatolian society of medical oncology). 1st NEMA Congress – 29 November- 02 December 2012 / Istanbul – Turkey. (0.14×7=0.98 points)
  17. Karaca H, Geredeli Ç, Kaplan MA, Demirci U, Alici S, Artaç M, Isikdogan A, Benekli M, Balakan O, Arpaci E, Budakoglu B, Uncu D, Guler T, Berk V, Ozkan M. The safety and efficacy of erlotinib in previously treated advanced non-small-cell lung cancer: multicenter experience. 1st NEMA Congress – 29 November- 02 December 2012 / Istanbul – Turkey. (0.14×7=0.98 points)
  18. Kefeli U, Benekli M, Sevinc A, Kaplan MA, Ciltas A, Balakan O, Isikdogan A, Yildiz R, Coskun U, Dane F, Harputluoglu H, Karaca H, Kaya AO, Demirci U, Gumus M, Buyukberber S. Efficacy of sorafenib in turkish patients with gastrointestinal stromal tumours in the third or fourth-line treatment; retrospective multicenter experience. 1st NEMA Congress – 29 November- 02 December 2012 / Istanbul – Turkey. (0.14×7=0.98 points)
  19. Kucukoner M, Isikdogan A, Sener C, Uyeturk U, Seker M, Tastekin D, Tonyali Ö, Balakan O, Yazici OK, Ozdemir N, Inal A, Kaplan MA, Suner A, Uncu D, Turkeli M, Demirci U, Urakci Z, Gumus M Boruban MC, Oksuzoglu B, Benekli M. Prımary gastrıc lymphoma: study of Anatolıan socıety of medıcal oncology. 1st NEMA Congress – 29 November- 02 December 2012 / Istanbul – Turkey. (0.14×7=0.98 points)
  20. International books or chapters in books:

None

  1. Articles published in national refereed journals
  2. Kıdır V, Aldemir M, Balakan O. Spontaneous retroperitoneal bleeding mimicking acute abdomen in hemophilia-A patients. Contemporary Surgery Journal, 17 (4), 243-47, (2003).
  3. Tankrikulu AC, Süner A, Balakan O, Aldemir M, Gurkan F. Diagnostic approach to abdominal tuberculosis cases. Contemporary Surgery Journal, 17 (4): 212-5, 2003.
  4. Aldemir M, Süner A, Kıdır V, Balakan O, Çelenk T. Spontaneous rupture of the spleen in a hemodialysis patient. European Journal of General Medicine, 1 (3) 51-54, (2004).
  5. Aldemir M, Güloğlu C, Balakan O, Süner A, Kaya Z. Thyrotoxic Periodic Paralysis: A case report and review of the literature. European Journal of General Medicine, 1 (2): 48-51, (2004).
  6. Soyoral Y, Süner A, Kıdır V, Arıtürk Z, Balakan O, Değertekin H. The effects of viral cirrhosis on cardiac ventricular function. European Journal of General Medicine, 1 (2): 15-18, 2004.
  7. Kıdır V, Balakan O, Süner A, Şit D, Ayyıldız O. A splenectomized thalassemia major case with multiple atrial thrombi. Turkish Journal of Hematology-Oncology, 15 (2): 100-103, 2005.
  8. Süner A, Balakan O, Kıdır V, Kara İ H. Coexistence of minor thalassemia and lead intoxication in a patient presenting with the hypochromic microcytic anemia. International Journal of Hematology-Oncology. 16 (3): 133-136, 2006.
  9. Balakan O, Kıdır V, Süner A, Yalçın K. Evaluation of our inflammatory bowel disease cases between 1995-2005 at Dicle University Medical Faculty Hospital. Düzce University Faculty of Medicine Journal, 3: 26-30, 2007.
  10. Kalender ME, Demiryürek S, Öztuzcu S, Kızılyer A, Demiryürek AY, Balakan O, Camcı C.. Gaziantep Medical investigation of the relationship between ROCK1 gene Lys222Glu and Arg1262Gln polymorphisms and breast cancer. Gaziantep Medical Journal. 17 (2): 77-81, 2011.
  11. Suner A, Tutar E, Kalender ME, Kazancı Ü, Arslan SK, Balakan O, Karataş E, Kanlıkama M. The relationship between prognostic parameters and tumor-associated tissue eosinophilia in supraglottic laryngeal tumors. 40 (1): 45-49, 2013 (0.18 × 15 = 2.7 points)
  12. Balakan O, Sevinc A. What Can We Do Towards Better Survival In Malign Melanoma Brain Metastasis? What Should We Do for an Improved Survival in Metastatic Malignant Melanoma with Brain Metastasis? Turkey-Special Topics Clinical J Med Oncol 2014; 7 (2): 75-82. (0.95 × 25 = 23.75 points)
  13. Papers presented at national scientific meetings and published in proceedings:
  14. Ayyıldız O, Kıdır V, Söker M, Işıkdoğan A, Süner A, Kara İ H, Balakan O, Çelik M, Müftüoğlu E. Long-term follow-up results of our patients with acute and chronic idiopathic thrombocytopenia: a prospective and retrospective combined study. Turkish Hematology Association, 31st National Congress, 23-28 September 2004, Antalya.
  15. Süner A, Balakan O, Kıdır V, Kara İ H. Coexistence of minor thalassemia and lead intoxication in a patient presenting with the hypochromic microcytic anemia. 3. National Family Medicine Days (with international participation). 25-28 May 2005, Kuşadası.
  16. Yalçın K, Yakut M, Seven G, Balakan O, Değertekin H. Clinical, serological, etiological and prognostic features of acute liver failure; a multicenter retrospective study. 5th National Hepatology Congress. 5-7 June 2005 Istanbul.
  17. Balakan O, Kıdır V, Yalçın K, Değertekin H. Cytokine levels in Chronic Hepatitis Delta and B virus infection. 22nd National Gastroenterology Week. 30 August – 4 September 2005, Malatya.
  18. Balakan O, Yalçın K, Süner A, Batun S. Lymphocyte CD ratios in Chronic Hepatitis Delta and B virus infection. 22nd National Gastroenterology Week. 30 August – 4 September 2005, Malatya.
  19. Balakan O, Kıdır V, Süner A, Yalçın K. Evaluation of our cases with inflammatory bowel disease. 22nd National Gastroenterology Week. 30 August – 4 September 2005, Malatya.
  20. Sevinç A, Kalender ME, Camcı C, İğci M, Tutar E, Öztuzcu S, Göğebakan B, Balakan O, Cengiz B. The frequency of mutations in c-kit and PDGFRA genes in gastrointestinal stromal tumors. 6th National Medical Oncology Congress 24-28 September 2009, Antalya
  21. Yıldız R, Büyükberber S, Yıldırım Özdemir N, Berk V, Kaplan MA, Üner A, Alkış N, Coşkun U, Uncu D, Balakan O, Camcı C, Yamaç D, Işıkdoğan A, Yetişyiğit T, Özkan M, Dane F , Altınbaş M, Zengin N, Benekli M. Evaluation of toxicity and response of multiple chemotherapy regimens with Bevacizumab combination in patients with metastatic colorectal cancer: a multicenter retrospective study (ATOD). 6th National Medical Oncology Congress 24-28 September 2009, Antalya
  22. Turan N, Dane F, Büyükberber S, Ustaalioğlu BÖ, Berk V, Özdemir N, Küçüköner M, Gümüş M, Balakan O, Özkan M, Coşkun U, Spotted M. M-adjuvant following surgical complete resection in liver metastatic colorectal cancers chemotherapy applications. 7. National Medical Oncology Congress 22-26 September 2010 Antalya.
  23. Balakan O, Süner A, Sevinç A, Balık A, Camcı C. A case of lymphangioma mimicking a metastatic liver tumor. 7. National Medical Oncology Congress 22-26 September 2010 Antalya.
  24. Cengiz B, Çoban S, Camcı C, Öztuzcu S, Aksoy B, Balakan O, Göğebakan B, Kaplan DS, Başkonuş İ, Balık A. CDC25A gene -350C / T, and -51 C / G polymorphism in pancreatic cancers. 7. National Medical Oncology Congress 22-26 September 2010 Antalya.
  25. İnal A, Köş FT, Algın E, Yıldız R, Berk V, Ünek İT, Çolak D, Küçüköner M, Elkıran ET, Helvacı K, Geredeli Ç, Dane F, Balakan O, Kaplan MA, Gök Durnalı A, Harputluoğlu H , Göksel G, Özdemir N, Büyükberber S, Gümüş M, Özkan M, Işıkdoğan A. Prognostic factors affecting survival in patients receiving gemcitabine and gemcitabine + cisplatin in locally advanced and metastatic pancreatic cancer (ATOD study). 8. National Medical Oncology Congress. Antalya 2011
  26. İnal A, Işıkdoğan A, Köş FT, Algın E, Gümüş G, Dikilitaş M, Elkıran ET, Helvacı K, Geredeli Ç, Dane F, Balakan O, Gök Durnalı A, Harputluoğlu H, Göksel G, Özdemir N, Kaplan MA , Özkan M, Uncu D, Büyükberber S. Retrospective evaluation of gemcitabine and gemcitabine + cisplatin combination efficacy and toxicity in locally advanced and metastatic pancreatic cancer: ATOD study. 3. National gastrointestinal oncology congress. 07-10 April 2011 Antalya.
  27. İnal A, Öztürk SC, İnanç M, Geredeli Ç, Receiver S, Harputluoğlu H, Çolak D, Sonmez ÖU, Balakan O, Doğu GG, Göksel G, Işıkdoğan A. Elderly breast cancer dignity; Tumor characteristics (ATOD study). 8. National Medical Oncology Congress. Antalya 2011.
  28. Karaca H, Geredeli Ç, Kaplan MA, Demirci U, Buyer S, Börücü MC, Işıkdoğan A, Spotted M, Balakan O, Arpacı E, Budakoğlu B, Uncu D, Güler T, Özkan Ö. Evaluation of efficacy and side effects of erlotinib treatment in patients with non-small cell lung carcinoma (ATOD study). 8. National Medical Oncology Congress. Antalya 2011
  29. Karaca H, Özkan M, Ulaş A, Demirci U, Yıldırım Özdemir N, Berk V, Uysal Sönmez Ö, Küçüköner M, Alkış N, Uncu D, Gökoz Doğu S, Balakan O, Çolak D, Öven Ustaalioğlu B, Buyer S , Büyükberber S. Neuroendocrine tumor database: Multicenter retrospective evaluation (ATOD study). 8. National Medical Oncology Congress. Antalya 2011
  30. Küçüköner M, Abdurrahman Işıkdoğan, Üyetürk Ü, Öksüzoğlu B, Şeker M, Gümüş M, Tonyali Ö, Benekli M, Balakan O, Camcı C, Türkeli M, Demirci U, Büyükberber S. Clinical-pathological and prognostic analysis of primary gastric lymphoma Evaluation of characteristics: Multi-center ATOD Study. 8. National Medical Oncology Congress. Antalya 2011
  31. Balakan O, İnanç M, Sevinç A, Özkan M, Alı S, Camcı C. Retrospective evaluation of liposomal doxorubicin (Modified CALYPSO) data in patients with recurrent epithelial ovarian cancer (ATOD study). 8. National Medical Oncology Congress. Antalya 2011
  32. Camcı C, Sevinç A, Öztuzcu S, Ulaşlı M, Kalender ME; Süner A, Balakan O, Cengiz B, Bayraktar R, Arslan A. PARP-1 gene expression in patients with breast cancer. 8. National Medical Oncology Congress. Antalya 2011
  33. Camcı C, Sevinç A, Öztuzcu S, Ulaşlı M, Kalender ME, Süner A, Balakan O, Cengiz B, Geyik F, Arslan A. An alternative perspective to breast cancer: RHO / ROCK pathway. 8. National Medical Oncology Congress. Antalya 2011
  34. Berk V, Özdemir N, Özkan M, Aksoy S, Turan N, İnal A, Balakan O, Yaşar N, Ünal OÜ, Benekli M, Durnalı A, Çolak D. Evaluation of side effects: ATOD study. 8. National Medical Oncology Congress. Antalya 2011
  35. Turan N, Koca D, Ustaalioğlu BÖ, Dane F, Özdemir N, Ulaş A, Öztop İ, Gümüş M, Öztürk MA, Berk V, Küçüköner M, Üner A, Balakan O, Helvacı K, Özkan S, Yılmaz U, Benekli M, Büyükberber S. Contribution of bevacizumab combinations in M-adjuvant chemotherapy following complete surgical resection of liver metastatic colorectal cancers: ATOD study. 8. National Medical Oncology Congress. Antalya 2011

23.Turan N, Dane F, Koca D, Berk V, Ustaalioğlu BÖ, Üner A, Öztop İ, Helvacı K, Gümüş M, Özdemir N, Balakan O, Küçüköner M, Yılmaz U, Spotekli M, Büyükberber S. Lung metastatic colorectal Factors affecting survival following surgical complete resection in cancers: ATOD study. 8. National Medical Oncology Congress. Antalya 2011

  1. Balakan O, Kalender ME, Süner A, Balakan T, Sevinç A. A case of gemcitabine-induced gynecomastia in a male patient with pancreatic cancer. 8. National Medical Oncology Congress. Antalya 2011

25.Turan N, Koca D, Dane F, Özdemir N, Ustaalioğlu BÖ, Öztop I, Ulaş A, Berk V, Balakan O, Küçüköner M, Öztürk MA, Benekli M, Gümüş M, Yılmaz U, Özkan S, Büyükberber S. M-adjuvant chemotherapy applications following complete surgical resection in liver metastatic colorectal cancers. 3. National gastrointestinal oncology congress. 07-10 April 2011 Antalya.

  1. Ciltaş A, Koca D, Yılmaz U, Büyükberber S, İnal A, Öztop İ, Binicier Ç, Köş T, Işıkdoğan A, Özdemir N, Eşbah O, Recipient S, Balakan O, Coşkun U, Benekli M.Local forward rectum Retrospective evaluation of the efficacy and tolerability of neoadjuvant chemoradiotherapy in patients with cancer: ATOD study. 3. National gastrointestinal oncology congress. 07-10 April 2011 Antalya.
  2. Yılmaz M, Kalender E, Balakan O, Süner A, Çelen Z, Camcı, C. The role of PET-CT in the staging of esophageal cancer. 3. National gastrointestinal oncology congress. 07-10 April 2011 Antalya.
  3. Sevinç A, Şeker M, Balakan O, Yıldız R, Kaplan MA, Cihan S, Karca H, Gökdurnalı A, Büyükberber S. Evaluation of patients receiving sunitinib treatment in patients with gastrointestinal stromal tumors: a multicenter study. 3. National gastrointestinal oncology congress. 07-10 April 2011 Antalya.
  4. Cengiz B, Çoban S, Camcı C, Öztuzcu S, Aksoy B, Balakan O, Göğebakan B, Arslan A, Başkonuş İ, Balık A. Relationship between CDC25A gene expression and promoter polymorphisms in pancreatic cancers. 3. National gastrointestinal oncology congress. 07-10 April 2011 Antalya.
  5. Ciltaş A, Büyükberber S, Yıldız R, Arpacı E, Budakoğlu B, Küçüköner M, Şendur MA, Balakan O, Kefeli U, Berk V, Harputluoğlu H, Öksüzoğlu B, Uncu D, Alkış N, Gümüş M, Spotted M, Coşkun U. Evaluation of Efficacy and Toxicity of Cisplatin + Capecitabine Chemotherapy in Patients with Locally Advanced and Metastatic Gastric Cancer (Multi-center ATOD Study). 4 national gastrointestinal oncology congresses 11-15 April 2012 Antalya

31.Berk V, Özdemir N, Özkan M, Aksoy S, Turan N, İnal A, Balakan O, Yaşar N, Ünal OÜ, Durnalı A, Çolak D, Uysal Sönmez Ö, Benekli M. In Second Stage Treatment in Patients with Advanced Pancreatic Cancer Comparison of XELOX and FOLFOX4: ATOD Study. 4 national gastrointestinal oncology congresses 11-15 April 2012 Antalya

  1. Balakan O, Özkara E, Öztuzcu S, Camcı C, Arslan A, Demiryürek AT. Investigation of the relationship between RhoC gene polymorphism and colorectal cancer. 4 national gastrointestinal oncology congresses 11-15 April 2012 Antalya
  2. Öztuzcu S, Özkara E, Süner A, Ulaşlı M, Balakan O, Demiryürek AT, Camcı C. Investigation of the relationship between endothelin 3 (EDN3) gene rs12322 polymorphism and colorectal cancer. 4 national gastrointestinal oncology congresses 11-15 April 2012 Antalya
  3. Balakan O, Özkara E, Öztuzcu S, Camcı C, Arslan A, Demiryürek AT. Investigation of the relationship between RhoB gene polymorphism and colorectal cancer. 4 national gastrointestinal oncology congresses 11-15 April 2012 Antalya
  4. Balakan O, Özkara E, Öztuzcu S, Camcı C, Arslan A, Demiryürek AT. Investigation of the relationship between RhoA gene polymorphism and colorectal cancer. 4 national gastrointestinal oncology congress 11-15 April 2012 Antalya.

Association and Organization Memberships:

Memberships of Scientific Organizations:

Medical Oncology Association

Anatolian Medical Oncology Association

X